Radioligand Therapy With 177Lu-PSMA for Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis

被引：134
作者：
Yadav, Madhav Prasad [1 ]
Ballal, Sanjana [1 ]
Sahoo, Ranjit Kumar [2 ]
Dwivedi, Sada Nand [3 ]
Bal, Chandrasekhar [1 ]
机构：
[1] All India Inst Med Sci, Dept Nucl Med, New Delhi 110029, India
[2] All India Inst Med Sci, Dept Med Oncol, New Delhi, India
[3] All India Inst Med Sci, Dept Biostat, New Delhi, India
来源：
AMERICAN JOURNAL OF ROENTGENOLOGY | 2019年 / 213卷 / 02期
关键词：
Lu-177-PSMA; castration-resistant prostate cancer; efficacy; lutetium-177; metastasis; prostate-specific membrane antigen; radioligand therapy; safety; MITOXANTRONE PLUS PREDNISONE; MEMBRANE ANTIGEN; MONOCLONAL-ANTIBODY; PHASE-II; PSMA; DOSIMETRY; SURVIVAL; LU-177-DKFZ-PSMA-617; ABIRATERONE; DOCETAXEL;
D O I：
10.2214/AJR.18.20845
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OBJECTIVE. Several clinical studies have shown the efficacy of Lu-177-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for metastatic castration-resistant prostate cancer (mCRPC). The purpose of this article is to present results of a systematic review and meta-analysis aimed at compiling and outlining efficacy and safety data on Lu-177-PSMA RLT for mCRPC across all studies published to date. CONCLUSION. The results of the systematic review and meta-analysis suggest that Lu-177-PSMA RLT is an effective treatment of advanced-stage mCRPC that is refractory to standard therapeutic options and that it has a low toxicity profile. High-level evidence from randomized control trials is crucial for confirming the effectiveness of Lu-177-PSMA RLT and for instituting this therapy in the routine clinical care of patients with mCRPC.
引用
收藏
页码：275 / 285
页数：11
相关论文
共 40 条
[1]   The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions [J].
Afshar-Oromieh, Ali ;
Hetzheim, Henrik ;
Kratochwil, Clemens ;
Benesova, Martina ;
Eder, Matthias ;
Neels, Oliver C. ;
Eisenhut, Michael ;
Kuebler, Wolfgang ;
Holland-Letz, Tim ;
Giesel, Frederik L. ;
Mier, Walter ;
Kopka, Klaus ;
Haberkorn, Uwe .
JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (11) :1697-1705
[2]   Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [177Lu]Lu-PSMA-617 [J].
Ahmadzadehfar, Hojjat ;
Wegen, Simone ;
Yordanova, Anna ;
Fimmers, Rolf ;
Kuerpig, Stefan ;
Eppard, Elisabeth ;
Wei, Xiao ;
Schlenkhoff, Carl ;
Hauser, Stefan ;
Essler, Markus .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (09) :1448-1454
[3]   Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer [J].
Ahmadzadehfar, Hojjat ;
Eppard, Elisabeth ;
Kuerpig, Stefan ;
Fimmers, Rolf ;
Yordanova, Anna ;
Schlenkhoff, Carl Diedrich ;
Gaertner, Florian ;
Rogenhofer, Sebastian ;
Essler, Markus .
ONCOTARGET, 2016, 7 (11) :12477-12488
[4]   Early side effects and first results of radioligand therapy with 177Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study [J].
Ahmadzadehfar, Hojjat ;
Rahbar, Kambiz ;
Kuerpig, Stefan ;
Boegemann, Martin ;
Claesener, Michael ;
Eppard, Elisabeth ;
Gaertner, Florian ;
Rogenhofer, Sebastian ;
Schaefers, Michael ;
Essler, Markus .
EJNMMI RESEARCH, 2015, 5 :1-8
[5]  
[Anonymous], COCHRANE DATABASE SY
[6]   Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer [J].
Bander, NH ;
Milowsky, MI ;
Nanus, DM ;
Kostakoglu, L ;
Vallabhajosula, S ;
Goldsmith, SJ .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (21) :4591-4601
[7]   177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy [J].
Baum, Richard P. ;
Kulkarni, Harshad R. ;
Schuchardt, Christiane ;
Singh, Aviral ;
Wirtz, Martina ;
Wiessalla, Stefan ;
Schottelius, Margret ;
Mueller, Dirk ;
Klette, Ingo ;
Wester, Hans-Juergen .
JOURNAL OF NUCLEAR MEDICINE, 2016, 57 (07) :1006-1013
[8]   177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer [J].
Braeuer, Axel ;
Grubert, Lena Sophie ;
Roll, Wolfgang ;
Schrader, Andres Jan ;
Schaefers, Michael ;
Boegemann, Martin ;
Rahbar, Kambiz .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (10) :1663-1670
[9]   Lutetium-177-labelled anti-prostate-specific membrane antigen antibody and ligands for the treatment of metastatic castrate-resistant prostate cancer: a systematic review and meta-analysis [J].
Calopedos, R. J. S. ;
Chalasani, V. ;
Asher, R. ;
Emmett, L. ;
Woo, H. H. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2017, 20 (03) :352-360
[10]   Abiraterone and Increased Survival in Metastatic Prostate Cancer [J].
De Bono, Johann S. ;
Logothetis, Christopher J. ;
Molina, Arturo ;
Fizazi, Karim ;
North, Scott ;
Chu, Luis ;
Chi, Kim N. ;
Jones, Robert J. ;
Goodman, Oscar B., Jr. ;
Saad, Fred ;
Staffurth, John N. ;
Mainwaring, Paul ;
Harland, Stephen ;
Flaig, Thomas W. ;
Hutson, Thomas E. ;
Cheng, Tina ;
Patterson, Helen ;
Hainsworth, John D. ;
Ryan, Charles J. ;
Sternberg, Cora N. ;
Ellard, Susan L. ;
Flechon, Aude ;
Saleh, Mansoor ;
Scholz, Mark ;
Efstathiou, Eleni ;
Zivi, Andrea ;
Bianchini, Diletta ;
Loriot, Yohann ;
Chieffo, Nicole ;
Thian Kheoh ;
Haqq, Christopher M. ;
Scher, Howard I. .
NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (21) :1995-2005
1234